Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Common Equity (2020 - 2025)

Historic Common Equity for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to $89.2 million.

  • Treace Medical Concepts' Common Equity fell 1498.39% to $89.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.2 million, marking a year-over-year decrease of 1498.39%. This contributed to the annual value of $112.9 million for FY2024, which is 1815.74% down from last year.
  • According to the latest figures from Q3 2025, Treace Medical Concepts' Common Equity is $89.2 million, which was down 1498.39% from $97.6 million recorded in Q2 2025.
  • In the past 5 years, Treace Medical Concepts' Common Equity registered a high of $157.6 million during Q1 2023, and its lowest value of -$684000.0 during Q1 2021.
  • For the 5-year period, Treace Medical Concepts' Common Equity averaged around $100.3 million, with its median value being $102.9 million (2021).
  • Over the last 5 years, Treace Medical Concepts' Common Equity had its largest YoY gain of 13016708.86% in 2021, and its largest YoY loss of 13791.57% in 2021.
  • Over the past 5 years, Treace Medical Concepts' Common Equity (Quarter) stood at $93.1 million in 2021, then crashed by 34.97% to $60.5 million in 2022, then skyrocketed by 127.89% to $137.9 million in 2023, then fell by 18.16% to $112.9 million in 2024, then decreased by 21.0% to $89.2 million in 2025.
  • Its Common Equity stands at $89.2 million for Q3 2025, versus $97.6 million for Q2 2025 and $105.3 million for Q1 2025.